The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies

Chang Moo Kang, Michele L. Babicky, Andrew M. Lowy

Research output: Contribution to journalReview article

15 Citations (Scopus)


Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

Original languageEnglish
Pages (from-to)183-189
Number of pages7
Issue number2
Publication statusPublished - 2014 Mar 1


All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this